RxDoctor Payments DataLook up a doctor →

Lauren Demarco

Adult Health · Boonton, NJNPI 1992164602

Payments from drug & device makers

$11,050in general payments, 2019–2025

Across 684 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$591
  • Lilly USA, LLC$580
  • Pfizer$569
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$8007%
  • Travel & lodging$561%
  • Food & beverage$10,16892%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,050 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,782
Medicare patients
135
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$139,496
FarxigaDapagliflozin Propanediol64$82,667
EliquisApixaban25$41,587
JanuviaSitagliptin Phosphate34$38,595
MounjaroTirzepatide24$28,546
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,633
WegovySemaglutide17$24,303
TrulicityDulaglutide13$12,780
VascepaIcosapent Ethyl11$8,966
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,641
Vilazodone Hcl14$2,469
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,392
Levothyroxine Sodium207$2,306
Atorvastatin Calcium251$2,277
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid16$2,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,593$163,798103 claims
AstraZenecaFarxiga$284$82,66764 claims
PfizerEliquis$569$41,58725 claims
Lilly USA, LLCMounjaro, Trulicity$580$41,32537 claims
MerckJanuvia$189$38,59534 claims
GSKTrelegy Ellipta$188$25,63327 claims
AbbVieSynthroid$1,774$1,14126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Boonton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →